索拉非尼相关手足皮肤反应的研究进展  

Researchprogress of sorafenib associated hand-foot skin reactions

作　　者：赵玉娜 刘青 高婷 何艳萍 雷亚亚 姜娟[2] ZHAO Yu-na;LIU Qing;GAO Ting;HE Yan-ping;LEI Ya-ya;JIANG Juan(Preparation center,General Hospital of Ningxia Medical University,Ningxia Yinchuan 750004,China;Department of Pharmacy,The Second Hospital of Lanzhou University,Gansu Lanzhou 730000,China)

机构地区：[1]宁夏医科大学总医院制剂中心,宁夏银川750004 [2]兰州大学第二医院药学部,甘肃兰州730000

出　　处：《中国医院药学杂志》2022年第22期2430-2433,共4页Chinese Journal of Hospital Pharmacy

摘　　要：甲苯磺酸索拉非尼是一种口服多激酶抑制剂,自2005年12月获得FDA批准以来,已成为无法切除的肝细胞癌的一线治疗药物。索拉非尼已被证实具有较好的安全性,但是手足皮肤反应作为其最常见的不良反应,虽然不危及生命,但可导致药物剂量改变或中断用药,从而限制抗肿瘤作用。本文就索拉非尼引起手足皮肤反应的临床特征、发病机制、预防及患者管理策略等进行综述,以期为该不良反应的临床管理和防治提供参考,提高患者用药依从性和抗肿瘤效果。Sorafenib tosylate is a multikinase inhibitor that has been approved by the FDA since December 2005.It has become a first-line in the treatment unresectable hepatocellular carcinoma.It has been proved to have good safety.But as the most common adverse reaction, although HFSR is not life-threatening, it may lead to dose change or interruption, thereby limiting the anti-tumor effect.In this paper, the clinical characteristics, pathogenesis, prevention and management of HFSR induced by sorafenib were reviewed.In order to provide reference for the clinical management and prevention of this adverse reaction, improve the drug compliance and anti-tumor effect of patients.

关 键 词：索拉非尼 多激酶抑制剂 手足皮肤反应 

分 类 号：R730.5[医药卫生—肿瘤]